TransPharm is a Horizon Europe research and innovation project which aims to support the transition towards the development, production and use of sustainable pharmaceuticals by showing leadership in i) technological innovation and ii) the transition to sustainability which is most impactful for the future of this sector. This is articulated in two tracks that aim to improve the European readiness for sustainable production of small molecules (APIs) that have environmental or supply concerns, i.e., i) Benign-by-Design (directed towards sustainable APIs); and ii) integrated flow chemistry (directed towards sustainable and secured production).
To reach the envisaged aims, the project will deliver four toolboxes for the development of greener pharmaceutical products and APIs, with the aim of:
analysing and predicting flow behaviour and environmental biodegradability of APIs and their synthesis pathways;
identifying greener and more sustainable alternatives to pharmaceutical products / APIs of concern;
reducing the footprint in synthetic schemes of APIs; and
assessing the sustainability of pharmaceuticals over their entire life cycle.
These toolboxes will be used to assess the potential to move towards greener pharmaceutical production. In addition, the project will elaborate on business cases for sustainable pharmaceutical products or APIs and what is needed to bring them to the market. The project will also make sure that key project results and knowledge are properly transferred towards stakeholders.
This project contributes to the EU strategic approach to pharmaceuticals in the environment, and to the Pharmaceutical strategy for Europe called for diversifying and secure supply chains and environmentally sustainable pharmaceuticals.
The aim of this EU-funded H2020 RISE is to bring together subject matter experts from the academic and non-academic sectors to develop and establish proof-of-concept of the utility of a new platform for fast and general elucidation of the interaction between proteins and RNA. The development of analytical methods for identification of RNA-binding proteins (RPBs) and their corresponding RNA motifs, will facilitate:
i) a deeper understanding of the roles of gene regulation and protein expression;
ii) accelerate development of personalized medicines via regulation of protein expression; and
iii) enable rapid identification of proteomes involved in specific diseases.
In doing so, this project will have outputs which in the medium term will have significant market opportunities and societal benefits, including, but not limited to, stimulating job creation in the pharmabiotech and diagnostics sectors; and in the longer term reducing costs for national and EU healthcare budgets. In order to achieve this overall aim, the proposal brings together 3 partners with complementary and synergizable skills:
Aristotle University of Thessaloniki (AUTh): expertise in proteomics and in particular structure elucidation and characterization of macromolecules such as protein-ligand complexes using mass spectrometry
KelAda Pharmachem Ltd (KelAda): expertise in medicinal chemistry and chemical process development
Central European Institute of Technology – Masaryk University (CEITEC-MU): expertise in biomolecular NMR spectroscopy and RNA synthesis
The aim of this EU-funded H2020 RISE project is to bring together subject matter experts from the academic and non-academic sectors to develop and exemplify the use of new catalysts and new green reactions to manufacture important halogenated compounds that could be used in drug discovery and drug production. In order to achieve this objective the proposal brings together 3 partners with complementary skills:
University of Naples (UNINA): expertise in medicinal chemistry and drug discovery.
KelAda Pharmachem: expertise in green chemistry, chemical batch process development and scale-up.
University of Córdoba (UCO): expertise in process engineering of continuous flow processes.
The aim of this EU-funded H2020 RISE project is to bring together subject matter experts from the academic and non-academic sectors to develop three new categories of quaternary ammonium salts to be used as catalysts for the cost-efficient and green manufacture of high value active pharmaceutical ingredients. In order to achieve this objective the proposal brings together 3 partners with complementary skills:
University of Naples (UNINA) – experts in the preparation and purification of cyclic peptides; experts in solid phase synthesis and immobilization of peptides on solid support.
KelAda Pharmachem – Phase-transfer catalysis/organocatalysis/scale-up of chemical processes
University of Linz (JKU) – experts in the design of novel chiral ammonium salts and optimisation of enantioselective phase-transfer catalytic processes.
The aim of this EU-funded H2020 RISE project is to bring together subject matter experts from the academic and non-academic sectors to develop a platform of “green” chemoenzymatic methods for the production of high-value active pharmaceutical ingredients – both those currently on the market, and those in development pipelines of the Pharma industry. The partners will exemplify the use of the platform through its application in the production of 4 drugs currently on the market – namely Duloxetine, Atomexetine, Ramosetron and Paricalcitol. In order to achieve this objective the proposal brings together 3 partners with complementary skills:
KelAda Pharmachem – phase transfer catalysis/organo catalysis/scale-up of chemical processes
Cerbios Pharma – biocatalysis and fermentation methodologies for drug production
Institute of Crystallography - National Research Council (IC-CNR) – protein crystallography and enzymatic engineering.